April 23, 2018 05:08 PM EDTUpdated 05:34 PM

FDA orders a partial hold on Epizyme’s lead cancer drug tazemetostat following T-cell lymphoma case

Epizyme $EPZM is in some hot water this evening after the biotech revealed a partial clinical hold on its crucial program for tazemetostat.

The Cambridge …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA or­ders a par­tial hold on Epizyme’s lead can­cer drug tazeme­to­stat fol­low­ing T-cell lym­phoma case